neurostimulation devices - global pipeline analysis

1. Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

2. The Global Neurostimulation Devices Market is Forecast to Reach $4.7 Billion by 2017 The global neurostimulation devices market was valued at $1.8 billion in 2010 and is expected to grow at a compound annual growth rate (CAGR) of 14% to reach $4.7 billion by 2017. The spinal cord stimulation (SCS) devices market is the largest segment of the neurostimulation devices market. The SCS devices market accounted for $1,089m in 2010 and is estimated to grow at a CAGR of 15% to reach $2,819m in 2017. The neurostimulation devices market is poised for rapid growth as a lot of research is being undertaken on neurostimulation therapy for the treatment of various indications, such as Parkinson’s disease, chronic pain, epilepsy, and depression. The introduction of more technologically advanced neurostimulation devices and the growing disease prevalence and incidence is expected to drive growth in the future. The rise in research and development (R&D) in this segment, as well as rising healthcare spending, will further encourage innovation in this field. The increasing elderly population and consequent rise in disease incidence will compound the growing demand for newer and more advanced neurostimulation devices. The neurostimulation devices segment has a strong pipeline, with a number of companies engaged in the development of innovative neurostimulator products. Support from regulatory bodies including the FDA (Food and Drug Administration) will also drive investment in the neurostimulation devices market, which will result in the development of improved and more efficient neurostimulators.

3. The US is the largest market in the neurostimulation devices segment with about a 70% share of global sales. The neurostimulation devices market in the US was valued at $1,300m in 2010. It is estimated to grow at a CAGR of 15% to reach $3,524m in 2017. The increasing elderly population and demand for more alternative therapies are the key drivers for market growth in the US. Several companies in the US, which specialize in different segments of the neurostimulation devices market, are responsible for the strong pipeline. Cyberonics, Inc., which is headquartered in the US, specializes in vagus nerve stimulation (VNS) devices. Companies such as Medtronic, Inc. and Boston Scientific Corporation are also based in the US and have strong pipelines in different neurostimulation devices segments. The US market for neurostimulation devices faces challenges such as limited approvals from the FDA and reimbursement issues with the CMS (Centers for Medicare and Medicaid Services). Medtronic, Inc. is the Global Leader in the Neurostimulation Devices Segment For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Neurostimulation-Devices-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017&Title=Medical_Devices&ReportType=Industry_Report

4. Medtronic, Inc. is the leading company in the global neurostimulation devices market with a 54% share of global sales in 2010. The company accounted for revenues of about $1.5 billion from its neurostimulation devices segment in 2010. It is the largest medical device company, with more than 38,000 employees globally and sales operations in more than 120 countries Medtronic’s neurostimulation devices segment offers deep brain stimulation (DBS) devices for the treatment of epilepsy, depression, chronic pain, fecal incontinence and obsessive-compulsive disorder. Its marketed products include RestoreULTRA, ACTIVA RC/PC and Soletra, which are FDA approved and key products used globally. RestoreULTRA is the thinnest neurostimulation device on the global market. It is used as a treatment for chronic pain. The company has a strong pipeline, which includes devices for the treatment of epilepsy, Parkinson’s disease, incontinence and new indications, such as obesity and heart failure. Neurostimulation Therapy Being Used as Treatment Option for Multiple Indications to Drive Growth in the Future The global neurostimulation devices market has a strong portfolio of products in the DBS, VNS, SCS, SNS (Sacral Nerve Stimulation) and CS (Cortical Stimulation) devices. Neurostimulation devices are currently used in the treatment of Parkinson’s disease essential tremor, stroke, urinary incontinence, epilepsy, depression and other neurodegenerative disorders. The products under development are expanding to indications such as chronic angina, heart failure, diabetes, and obesity. This is

5. expected to increase the demand for neurostimulation devices in future. GlobalData’s new report, “Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global neurostimulation devices market. The report provides market landscape, competitive landscape and market trends information on the neurostimulation devices market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Neurostimulation-Devices-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017&Title=Medical_Devices&ReportType=Industry_Report visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782